Walid L. Shaib

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al. · The Lancet · 2018 · 1.3K citations · Full text

Pembrolizumab Versus Paclitaxel, Gastrointestinal Oncology, Medicine +7

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma

Vincenzo Mazzaferro, Bassel F. El‐Rayes, Michele Droz Dit Busset et al. · British Journal of Cancer · 2018 · 375 citations · Full text

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo et al. · The Lancet Oncology · 2019 · 276 citations · Full text

First-line Therapy, Gastrointestinal Oncology, Medicine +6

The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced‐stage cancer treated with immunotherapy

Mehmet Asım Bilen, Dylan J. Martini, Yuan Liu et al. · Cancer · 2018 · 157 citations · Full text

Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy

Mehmet Asım Bilen, Julie M. Shabto, Dylan J. Martini et al. · BMC Cancer · 2019 · 121 citations · Full text